HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -8.90K | 236.50K | 52.80K | 170.80K | 18.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.90K | 236.50K | 52.80K | 170.80K | 18.20K |
| Cost of Revenue | 52.90K | 84.80K | 35.70K | 117.10K | 13.60K |
| Gross Profit | -61.80K | 151.70K | 17.10K | 53.70K | 4.60K |
| SG&A Expenses | 376.20K | 477.90K | 666.90K | 880.60K | 1.22M |
| Depreciation & Amortization | 100.00 | 100.00 | 17.10K | 130.50K | 104.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 470.90K | 690.00K | 831.80K | 1.23M | 1.44M |
| Operating Income | -479.80K | -453.50K | -779.00K | -1.06M | -1.42M |
| Income Before Tax | -513.10K | -1.86M | -912.70K | -8.97M | -1.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -513.10K | -1.86M | -912.70K | -8.97M | -1.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -513.10K | -1.86M | -912.70K | -8.97M | -1.73M |
| EBIT | -479.80K | -453.50K | -779.00K | -1.06M | -1.42M |
| EBITDA | -479.70K | -453.40K | -761.90K | -948.50K | -1.32M |
| EPS Basic | -0.05 | -0.31 | -0.17 | -1.88 | -0.41 |
| Normalized Basic EPS | -0.04 | -0.06 | -0.10 | -0.25 | -0.24 |
| EPS Diluted | -0.05 | -0.31 | -0.17 | -1.88 | -0.41 |
| Normalized Diluted EPS | -0.04 | -0.06 | -0.10 | -0.25 | -0.24 |
| Average Basic Shares Outstanding | 9.71M | 6.07M | 5.48M | 4.77M | 4.24M |
| Average Diluted Shares Outstanding | 9.71M | 6.07M | 5.48M | 4.77M | 4.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |